Skip to content
ppharmaranks
Menu
Class IIOngoing

Neupogen (filgrastim) For Injection recall

FDA recall D-0285-2025 · initiated Feb 27, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Mar 26, 2025How we research

Amgen, Inc. recalled Neupogen (filgrastim) For Injection in Feb 2025 — an FDA Class II recall (D-0285-2025) because Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: 1147300, 1147300A, Exp.: 2/28/2025; 1152064, Exp.:3/31/2025; 1154734, 1156806, Exp.: 8/31/2025; 1159109, Exp.: 10/31/2025; 1163909, Exp.: 2/28/2026; 1164631, Exp.: 5/31/2026; 1171366, 1182097, Exp.:8/31/2026; 1176114, Exp.: 2/28/2027; 1182094, Exp.:7/31/2027.

Quantity recalled: 313,620 Vials

Details

Product
Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative, Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-530-01 (vial), NDC 55513-530-10 (box).
Recalling company
Amgen Inc
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the U.S.A. and Belgium/Luxembourg, Brazil, Chile, Colombia, France/French Guiana, Germany, Ireland, Italy/San Marino, Netherlands, Poland, Spain/Andorra, Sweden, Finland, Switzerland/Liechtenstein, United Kingdom of Great Britain and Northern Ireland, Ireland, Denmark, Canada, Hong Kong, Philippines, Israel, Malaysia, Saudi Arabia, Gibraltar.
Initiated
Feb 27, 2025
FDA report date
Mar 26, 2025

This recall is linked to a product we cover: Neupogen

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Neupogen (filgrastim) For Injection recalled?
Amgen, Inc. recalled Neupogen (filgrastim) For Injection in Feb 2025 — an FDA Class II recall (D-0285-2025) because Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Neupogen (filgrastim) For Injection recalled?
Per the FDA enforcement record, the reason for recall D-0285-2025 was: Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
Is a recalled Neupogen (filgrastim) For Injection dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Neupogen (filgrastim) For Injection are affected?
Distributed: Nationwide in the U.S.A. and Belgium/Luxembourg, Brazil, Chile, Colombia, France/French Guiana, Germany, Ireland, Italy/San Marino, Netherlands, Poland, Spain/Andorra, Sweden, Finland, Switzerland/Liechtenstein, United Kingdom of Great Britain and Northern Ireland, Ireland, Denmark, Canada, Hong Kong, Philippines, Israel, Malaysia, Saudi Arabia, Gibraltar.. The recall covers these lots — Lot #: 1147300, 1147300A, Exp.: 2/28/2025; 1152064, Exp.:3/31/2025; 1154734, 1156806, Exp.: 8/31/2025; 1159109, Exp.: 10/31/2025; 1163909, Exp.: 2/28/2026; 1164631, Exp.: 5/31/2026; 1171366, 1182097, Exp.:8/31/2026; 1176114, Exp.: 2/28/2027; 1182094, Exp.:7/31/2027.. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0285-2025.

Source: openFDA Drug Enforcement record D-0285-2025

← All drug recalls